Navigating Breast Cancer Oligometastasis and Oligoprogression: Current Landscape and Future Directions

Overview

Journal Curr Oncol Rep

Publisher Current Science

Specialty Oncology

Date 2024 Apr 23

PMID 38652425

Authors

Stephanie M Yoon

Jose G Bazan

Affiliations

Soon will be listed here.

Abstract

Purpose: We examine the potential for curative approaches among metastatic breast cancer (MBC) patients by exploring the recent literature on local ablative therapies like surgery and stereotactic body radiation therapy (SBRT) in patients with oligometastatic (OM) breast cancer. We also cover therapies for MBC patients with oligoprogressive (OP) disease.

Key Findings: Surgery and SBRT have been studied for OM and OP breast cancer, mainly in retrospective or non-randomized trials. While many studies demonstrated favorable results, a cooperative study and single-institution trial found no support for surgery/SBRT in OM and OP cases, respectively.

Conclusion: While there is interest in applying local therapies to OM and OP breast cancer, the current randomized data does not back the routine use of surgery or SBRT, particularly when considering the potential for treatment-related toxicities. Future research should refine patient selection through advanced imaging and possibly explore these therapies specifically in patients with hormone receptor-positive or HER2-positive disease.

Citing Articles

The heterogeneity in oligoprogression and stereotactic body radiation therapy.

Hayashi T, Takigawa N Transl Cancer Res. 2025; 14(1):1-6.

PMID: 39974422 PMC: 11833369. DOI: 10.21037/tcr-24-1737.

Impact of HER2-targeting antibody drug conjugates in treatment strategies for patients with breast cancer.

Ma H, Li J Heliyon. 2025; 11(3):e41590.

PMID: 39916839 PMC: 11799954. DOI: 10.1016/j.heliyon.2024.e41590.

References

Halsted C, Benson J, Jatoi I . A historical account of breast cancer surgery: beware of local recurrence but be not radical. Future Oncol. 2014; 10(9):1649-57. DOI: 10.2217/fon.14.98. View

Fisher B, RAVDIN R, AUSMAN R, Slack N, Moore G, NOER R . Surgical adjuvant chemotherapy in cancer of the breast: results of a decade of cooperative investigation. Ann Surg. 1968; 168(3):337-56. PMC: 1387335. DOI: 10.1097/00000658-196809000-00004. View

Hellman S, Weichselbaum R . Oligometastases. J Clin Oncol. 1995; 13(1):8-10. DOI: 10.1200/JCO.1995.13.1.8. View

Palma D, Olson R, Harrow S, Gaede S, Louie A, Haasbeek C . Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial. Lancet. 2019; 393(10185):2051-2058. DOI: 10.1016/S0140-6736(18)32487-5. View

Gomez D, Tang C, Zhang J, Blumenschein Jr G, Hernandez M, Lee J . Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non-Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study. J Clin Oncol. 2019; 37(18):1558-1565. PMC: 6599408. DOI: 10.1200/JCO.19.00201. View

Ost P, Reynders D, Decaestecker K, Fonteyne V, Lumen N, De Bruycker A . Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial. J Clin Oncol. 2017; 36(5):446-453. DOI: 10.1200/JCO.2017.75.4853. View

Iyengar P, Wardak Z, Gerber D, Tumati V, Ahn C, Hughes R . Consolidative Radiotherapy for Limited Metastatic Non-Small-Cell Lung Cancer: A Phase 2 Randomized Clinical Trial. JAMA Oncol. 2017; 4(1):e173501. PMC: 5833648. DOI: 10.1001/jamaoncol.2017.3501. View

Chalkidou A, Macmillan T, Grzeda M, Peacock J, Summers J, Eddy S . Stereotactic ablative body radiotherapy in patients with oligometastatic cancers: a prospective, registry-based, single-arm, observational, evaluation study. Lancet Oncol. 2021; 22(1):98-106. DOI: 10.1016/S1470-2045(20)30537-4. View

Hurvitz S, Dirix L, Kocsis J, Bianchi G, Lu J, Vinholes J . Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol. 2013; 31(9):1157-63. DOI: 10.1200/JCO.2012.44.9694. View

10.

Albain K, Nag S, Calderillo-Ruiz G, Jordaan J, Llombart A, Pluzanska A . Gemcitabine plus Paclitaxel versus Paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment. J Clin Oncol. 2008; 26(24):3950-7. DOI: 10.1200/JCO.2007.11.9362. View

11.

Lievens Y, Guckenberger M, Gomez D, Hoyer M, Iyengar P, Kindts I . Defining oligometastatic disease from a radiation oncology perspective: An ESTRO-ASTRO consensus document. Radiother Oncol. 2020; 148:157-166. DOI: 10.1016/j.radonc.2020.04.003. View

12.

Guckenberger M, Lievens Y, Bouma A, Collette L, Dekker A, deSouza N . Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation. Lancet Oncol. 2020; 21(1):e18-e28. DOI: 10.1016/S1470-2045(19)30718-1. View

13.

AlSendi M, OReilly D, Zeidan Y, Kelly C . Oligometastatic breast cancer: Are we there yet?. Int J Cancer. 2021; 149(8):1520-1528. DOI: 10.1002/ijc.33693. View

14.

Perez-Garcia J, Cortez P, Gion M, Cortes J . Can we cure oligometastatic disease? A practical point of view. Curr Opin Oncol. 2020; 32(6):568-574. DOI: 10.1097/CCO.0000000000000684. View

15.

Ramadan S, Quan K, Schnarr K, Juergens R, Hotte S, Mukherjee S . Impact of stereotactic body radiotherapy (SBRT) in oligoprogressive metastatic disease. Acta Oncol. 2022; 61(6):705-713. DOI: 10.1080/0284186X.2022.2063067. View

16.

Nicosia L, Figlia V, Ricottone N, Cuccia F, Mazzola R, Giaj-Levra N . Stereotactic body radiotherapy (SBRT) and concomitant systemic therapy in oligoprogressive breast cancer patients. Clin Exp Metastasis. 2022; 39(4):581-588. DOI: 10.1007/s10585-022-10167-6. View

17.

Chikarmane S, Tirumani S, Howard S, Jagannathan J, DiPiro P . Metastatic patterns of breast cancer subtypes: what radiologists should know in the era of personalized cancer medicine. Clin Radiol. 2014; 70(1):1-10. DOI: 10.1016/j.crad.2014.08.015. View

18.

Maki D, Grossman R . Patterns of disease spread in metastatic breast carcinoma: influence of estrogen and progesterone receptor status. AJNR Am J Neuroradiol. 2000; 21(6):1064-6. PMC: 7973900. View

19.

OSullivan G, Carty F, Cronin C . Imaging of bone metastasis: An update. World J Radiol. 2015; 7(8):202-11. PMC: 4553252. DOI: 10.4329/wjr.v7.i8.202. View

20.

Pirasteh A, Lovrec P, Pedrosa I . Imaging and its Impact on Defining the Oligometastatic State. Semin Radiat Oncol. 2021; 31(3):186-199. DOI: 10.1016/j.semradonc.2021.03.006. View